Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INCY

Incyte Corp

Sep 15 • 04:00PM ET

83.14

+0.04 0.05 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD IONS BMY MRK JNJ AMGN PFE LLY

| Held by: VTI VB VOO RSP VBK SPY IVV XBI USMV IBB

Scroll to Statements

Index	S&P 500	P/E	18.90	EPS (ttm)	4.40	Insider Own	1.20%	Shs Outstand	194.12M	Perf Week	-3.95%
Market Cap	16.24B	Forward P/E	11.85	EPS next Y	7.02	Insider Trans	-2.99%	Shs Float	192.94M	Perf Month	-3.51%
Enterprise Value	13.86B	PEG	0.19	EPS next Q	1.60	Inst Own	102.40%	Short Float	3.89%	Perf Quarter	22.72%
Income	870.87M	P/S	3.54	EPS this Y	447.19%	Inst Trans	3.96%	Short Ratio	4.21	Perf Half Y	22.52%
Sales	4.58B	P/B	3.87	EPS next Y	19.20%	ROA	16.61%	Short Interest	7.51M	Perf YTD	20.37%
Book/sh	21.49	P/C	6.70	EPS next 5Y	97.89%	ROE	24.30%	52W High	87.99 -5.51%	Perf Year	31.70%
Cash/sh	12.40	P/FCF	16.95	EPS past 3/5Y	-66.90% -40.36%	ROIC	20.72%	52W Low	53.56 55.23%	Perf 3Y	15.92%
Dividend Est.	-	EV/EBITDA	12.77	Sales past 3/5Y	12.41% 14.46%	Gross Margin	91.43%	Volatility	2.21% 2.04%	Perf 5Y	-7.34%
Dividend TTM	-	EV/Sales	3.02	EPS Y/Y TTM	1088.27%	Oper. Margin	21.69%	ATR (14)	1.94	Perf 10Y	-28.25%
Dividend Ex-Date	-	Quick Ratio	2.78	Sales Y/Y TTM	18.87%	Profit Margin	18.99%	RSI (14)	49.67	Recom	2.44
Dividend Gr. 3/5Y	- -	Current Ratio	2.85	EPS Q/Q	200.00%	SMA20	-2.53%	Beta	0.74	Target Price	83.00
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	16.46%	SMA50	5.89%	Rel Volume	0.98	Prev Close	83.10
Employees	2617	LT Debt/Eq	0.01	Earnings	Jul 29 BMO	SMA200	18.54%	Avg Volume	1.78M	Price	83.14
IPO	Nov 04, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.22% 5.36%	Trades		Volume	1,740,952	Change	0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$89
Aug-01-25	Initiated	Barclays	Overweight	$90
Jun-16-25	Upgrade	Stifel	Hold → Buy	$107
Mar-18-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-18-25	Downgrade	Guggenheim	Buy → Neutral
Dec-17-24	Initiated	UBS	Neutral	$77
Oct-29-24	Upgrade	BofA Securities	Neutral → Buy	$68 → $90
Oct-01-24	Initiated	Wolfe Research	Outperform	$84
Sep-18-24	Downgrade	Truist	Buy → Hold	$83 → $74
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48
May-23-24	Initiated	Deutsche Bank	Hold	$55
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78
Dec-04-23	Upgrade	Guggenheim	Neutral → Buy	$86
Nov-21-23	Downgrade	Goldman	Buy → Neutral	$98 → $65
Jul-25-23	Initiated	Citigroup	Buy	$82
May-04-23	Downgrade	BofA Securities	Buy → Neutral	$84
Apr-10-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$81 → $79

Show Previous Ratings

Sep-11-25 11:15AM	Incyte Corporation (INCY) Advances KRAS Cancer Program (Insider Monkey)
Sep-10-25 07:30AM	Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress (Business Wire)
Sep-09-25 02:22PM	Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade. (Barrons.com)
Sep-05-25 11:01AM	Just What The Doctor Ordered: This Medical Stock Offers Fresh Entry Amid 60% Rally (Investor's Business Daily)
Sep-03-25 11:30AM	Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report? (Zacks)
09:15AM	Loading…
09:15AM	Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa (Business Wire)
Sep-02-25 03:35PM	Incyte (INCY) Stock Is Up, What You Need To Know (StockStory)
Aug-31-25 08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
Aug-29-25 07:14AM	Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype? (MarketBeat)
Aug-28-25 11:30AM	Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue? (Zacks)
04:57AM	Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership (Insider Monkey)
Aug-27-25 04:15PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-25-25 08:00AM	Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer (Business Wire)
Aug-22-25 09:39AM	AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth (Zacks)
12:33AM	2 Mooning Stocks with Exciting Potential and 1 We Ignore (StockStory)
10:18AM	Loading…
Aug-20-25 10:18AM	INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold? (Zacks)
08:55AM	Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? (Barchart)
Aug-19-25 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Aug-18-25 10:01AM	Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks (InvestorPlace)
Aug-17-25 11:33PM	Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers (StockStory)
Aug-15-25 02:50PM	Cancer Stock Soars While This China Tech Stock Heads To New Highs (Investor's Business Daily)
Aug-14-25 02:36PM	Harrow Stock Eyes Relative Strength Rating Upgrade (Investor's Business Daily)
Aug-13-25 12:15AM	INCY Q2 Deep Dive: Product Launches and Pipeline Progress Underpin Revenue Growth (StockStory) +5.20%
12:10AM	The Top 5 Analyst Questions From Incyte's Q2 Earnings Call (StockStory)
Aug-12-25 07:08PM	Analyst Report: Incyte Corporation (Morningstar Research)
09:10AM	Wells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight (Insider Monkey)
Aug-11-25 02:00AM	Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside. (Barrons.com)
Aug-07-25 02:00PM	Supernus Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Aug-06-25 09:36AM	Snap downgraded, Leidos upgraded: Wall Street's top analyst calls (The Fly)
08:45AM	Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer (GlobeNewswire)
04:05PM	Loading…
Aug-05-25 04:05PM	Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis (Business Wire)
Aug-04-25 04:30PM	Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America (GlobeNewswire)
Aug-01-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
09:34AM	Avis Budget downgraded, Sprouts upgraded: Wall Street's top analyst calls (The Fly)
Jul-31-25 04:30PM	Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil (GlobeNewswire)
Jul-30-25 09:40AM	Why Incyte (INCY) is a Top Value Stock for the Long-Term (Zacks)
08:50AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
03:04AM	Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
01:55AM	Analyst Report: Incyte Corporation (Morningstar Research)
Jul-29-25 02:40PM	Incyte (INCY) Stock Trades Up, Here Is Why (StockStory) +10.28%
11:45AM	INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales (Zacks)
09:30AM	Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
08:20AM	Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
07:48AM	Incyte (NASDAQ:INCY) Reports Strong Q2 (StockStory)
07:14AM	Incyte: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
Jul-28-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jul-27-25 11:04PM	Incyte (INCY) Q2 Earnings: What To Expect (StockStory)
Jul-24-25 11:47PM	Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects (Insider Monkey)
05:02PM	Incyte To Present Initial Data for its TGFR2PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 (Business Wire)
11:42AM	Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards? (Zacks)
10:00AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-23-25 10:53AM	Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? (Zacks)
Jul-22-25 10:00AM	Incyte (INCY) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-17-25 09:40AM	Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? (Zacks)
Jul-16-25 11:40AM	INCY or TECH: Which Is the Better Value Stock Right Now? (Zacks)
Jul-10-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
08:00AM	Incyte to Report Second Quarter Financial Results (Business Wire)
Jul-09-25 10:09AM	William Blair Maintains 'Hold' Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties (Insider Monkey)
Jul-02-25 04:30PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-25 09:33AM	Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? (Zacks)
Jun-30-25 09:15AM	Jim Cramer Highlights That Incyte's New CEO is an "Industry Veteran" (Insider Monkey)
Jun-27-25 01:14PM	Incyte Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
12:21PM	Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz (TipRanks)
Jun-26-25 04:45PM	Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role? (Investor's Business Daily)
09:16AM	Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes (Investor's Business Daily)
07:30AM	Incyte Appoints Bill Meury Chief Executive Officer; Herv Hoppenot to Retire (Business Wire)
Jun-24-25 03:05AM	How Is Incytes Stock Performance Compared to Other Biotech Stocks? (Barchart)
Jun-23-25 09:53AM	FDA Extends INCY's Application for Opzelura Label Expansion (Zacks)
12:19AM	5 Revealing Analyst Questions From Incyte's Q1 Earnings Call (StockStory)
Jun-20-25 04:30PM	Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis (Business Wire)
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 03:39PM	Incyte Announces FDA Approval of Monjuvi (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma (Business Wire)
Jun-17-25 12:08PM	Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics (Zacks)
09:35AM	Cisco upgraded, CoreWeave downgraded: Wall Streets top analyst calls (TipRanks)
Jun-16-25 08:27AM	QGEN Stock Rises in After Market Following Partnership With Incyte (Zacks) +5.12%
07:06AM	Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms (Medical Device Network)
Jun-15-25 05:49AM	Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches (Insider Monkey)
04:00AM	QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) (Business Wire)
03:15AM	Positive Late-Breaking Data for Incytes First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025 (Business Wire)
Jun-13-25 12:05PM	Specialised Therapeutics announces expanded partnership with Incyte (TipRanks)
Jun-12-25 06:45PM	Phase 3 Data for Incytes Retifanlimab (Zynyz) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet (Business Wire)
Jun-06-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:08PM	Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? (MarketWatch)
11:31AM	Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-05-25 11:30AM	Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? (Zacks)
Jun-03-25 10:30AM	Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025 (Business Wire)
May-29-25 07:58PM	Analyst Report: Incyte Corporation (Morningstar Research)
11:30AM	Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report? (Zacks)
May-27-25 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
May-22-25 12:02AM	3 Reasons INCY is Risky and 1 Stock to Buy Instead (StockStory)
May-20-25 05:06PM	S&P 500 Gains and Losses Today: FICO Stock Falls as Federal Housing Official Questions Pricing (Investopedia)
May-19-25 09:26AM	FDA approves Incytes retifanlimab combo for SCAC treatment (Pharmaceutical Technology)
May-16-25 10:51AM	Incyte Gets FDA Approval for Zynyz in New Cancer Indication (Zacks)
May-15-25 02:30PM	Incyte Announces FDA Approval of Zynyz (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States (Business Wire)
May-14-25 07:49AM	Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying (Insider Monkey)
May-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-06-25 01:13PM	Q1 2025 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 05:06AM	I Scanned The S&P 500 For GARP Stocks; Here's What I Found (Seeking Alpha)
May-01-25 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Denton Sheila A.	EVP & General Counsel	Sep 02 '25	Option Exercise	58.06	598	34,720	33,798	Sep 04 04:04 PM
Denton Sheila A.	EVP & General Counsel	Sep 02 '25	Sale	84.97	598	50,812	33,200	Sep 04 04:04 PM
SHEILA DENTON	Officer	Sep 02 '25	Proposed Sale	84.97	598	50,812		Sep 02 04:07 PM
Denton Sheila A.	EVP & General Counsel	Aug 15 '25	Option Exercise	64.25	277	17,797	33,477	Aug 19 04:13 PM
Denton Sheila A.	EVP & General Counsel	Aug 15 '25	Sale	86.81	277	24,046	33,200	Aug 19 04:13 PM
SHEILA DENTON	Officer	Aug 15 '25	Proposed Sale	86.81	277	24,046		Aug 15 04:05 PM
BARRY FLANNELLY	Officer	Aug 13 '25	Proposed Sale	82.51	75,963	6,267,540		Aug 13 04:18 PM
BARRY FLANNELLY	Officer	Aug 12 '25	Proposed Sale	80.00	14,037	1,122,970		Aug 12 04:21 PM
Denton Sheila A.	EVP & General Counsel	Aug 04 '25	Option Exercise	58.06	598	34,720	33,798	Aug 06 04:03 PM
Denton Sheila A.	EVP & General Counsel	Aug 04 '25	Sale	75.77	598	45,310	33,200	Aug 06 04:03 PM
SHEILA DENTON	Officer	Aug 04 '25	Proposed Sale	75.77	598	45,310		Aug 04 04:05 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 21 '25	Sale	67.94	3,706	251,786	102,886	Jul 23 03:56 PM
STEVEN STEIN	Officer	Jul 21 '25	Proposed Sale	67.94	3,706	251,786		Jul 21 04:01 PM
Flannelly Barry P	EVP & General Manager US	Jul 16 '25	Sale	68.36	1,340	91,602	35,149	Jul 17 04:06 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 16 '25	Sale	68.36	983	67,198	40,540	Jul 17 04:05 PM
Denton Sheila A.	EVP & General Counsel	Jul 15 '25	Option Exercise	64.25	3,330	213,952	29,834	Jul 17 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jul 15 '25	Sale	69.86	3,330	232,634	26,504	Jul 17 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jul 16 '25	Sale	68.36	785	53,663	33,200	Jul 17 04:04 PM
VIJAY IYENGAR	Officer	Jul 16 '25	Proposed Sale	68.36	983	67,198		Jul 16 04:07 PM
BARRY FLANNELLY	Officer	Jul 16 '25	Proposed Sale	68.36	1,340	91,602		Jul 16 04:06 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 14 '25	Sale	68.47	14,952	1,023,763	97,466	Jul 16 04:05 PM
SHEILA DENTON	Officer	Jul 16 '25	Proposed Sale	68.36	785	53,663		Jul 16 04:02 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 15 '25	Sale	69.86	1,177	82,225	35,929	Jul 16 04:02 PM
Flannelly Barry P	EVP & General Manager US	Jul 15 '25	Sale	69.86	1,192	83,273	37,630	Jul 16 04:02 PM
BARRY FLANNELLY	Officer	Jul 15 '25	Proposed Sale	69.86	1,192	83,273		Jul 15 04:41 PM
SHEILA DENTON	Officer	Jul 15 '25	Proposed Sale	69.86	3,330	232,634		Jul 15 04:37 PM
VIJAY IYENGAR	Officer	Jul 15 '25	Proposed Sale	69.86	1,177	82,225		Jul 15 04:20 PM
STEVEN STEIN	Officer	Jul 14 '25	Proposed Sale	68.47	14,952	1,023,714		Jul 14 04:03 PM
Flannelly Barry P	EVP & General Manager US	Jul 03 '25	Sale	68.15	10,903	743,039	39,744	Jul 07 04:46 PM
Denton Sheila A.	EVP & General Counsel	Jul 02 '25	Option Exercise	58.06	599	34,778	27,103	Jul 07 04:44 PM
Denton Sheila A.	EVP & General Counsel	Jul 02 '25	Sale	68.61	599	41,097	26,504	Jul 07 04:44 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 03 '25	Sale	68.15	8,617	587,275	37,701	Jul 07 04:43 PM
BARRY FLANNELLY	Officer	Jul 03 '25	Proposed Sale	68.15	10,903	743,048		Jul 03 03:10 PM
VIJAY IYENGAR	Officer	Jul 03 '25	Proposed Sale	68.15	8,617	587,272		Jul 03 02:46 PM
SHEILA DENTON	Officer	Jul 02 '25	Proposed Sale	68.61	599	41,097		Jul 02 04:27 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Option Exercise	58.06	1,795	104,218	28,299	Jun 05 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Sale	68.00	1,795	122,060	26,504	Jun 05 04:04 PM
SHEILA DENTON	Officer	Jun 03 '25	Proposed Sale	68.00	1,795	122,060		Jun 03 04:06 PM
Tray Thomas	Principal Accounting Officer	May 30 '25	Sale	65.71	963	63,279	22,654	Jun 03 04:00 PM
Tray Thomas	Principal Accounting Officer	Jun 02 '25	Sale	64.88	651	42,237	22,003	Jun 03 04:00 PM
THOMAS R TRAY	Officer	Jun 02 '25	Proposed Sale	64.88	651	42,237		Jun 02 04:26 PM
THOMAS R TRAY	Officer	May 30 '25	Proposed Sale	65.71	963	63,279		May 30 04:03 PM
Flannelly Barry P	EVP & General Manager US	Mar 14 '25	Sale	67.69	19,807	1,340,656	33,567	Mar 18 04:01 PM
BARRY FLANNELLY	Officer	Mar 14 '25	Proposed Sale	67.69	19,807	1,340,728		Mar 14 04:11 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Option Exercise	58.06	599	34,778	26,447	Mar 06 04:56 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Sale	69.99	599	41,924	25,848	Mar 06 04:56 PM
SHEILA DENTON	Officer	Mar 04 '25	Proposed Sale	69.99	599	41,924		Mar 04 05:12 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Option Exercise	58.06	9,574	555,866	39,917	Feb 28 06:34 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Sale	74.07	14,069	1,042,136	25,848	Feb 28 06:34 PM
SHEILA DENTON	Officer	Feb 26 '25	Proposed Sale	74.07	14,069	1,042,138		Feb 26 04:04 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 21 '25	Sale	72.69	12,352	897,867	66,967	Jan 22 04:05 PM
STEVEN STEIN	Officer	Jan 21 '25	Proposed Sale	72.69	12,352	897,906		Jan 21 04:03 PM
Tray Thomas	Principal Accounting Officer	Dec 13 '24	Sale	70.64	650	45,916	23,962	Dec 17 12:37 PM
Tray Thomas	Principal Accounting Officer	Dec 16 '24	Sale	69.31	650	45,052	23,312	Dec 17 12:37 PM
THOMAS R TRAY	Officer	Dec 16 '24	Proposed Sale	69.31	650	45,052		Dec 16 04:04 PM
Iyengar Vijay K	EVP, GMAPPS	Nov 29 '24	Sale	75.38	6,043	455,544	30,658	Dec 03 12:52 PM
VIJAY IYENGAR	Officer	Nov 29 '24	Proposed Sale	75.39	6,043	455,555		Nov 29 01:28 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Option Exercise	70.03	3,680	257,719	61,722	Nov 08 12:48 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Sale	79.68	3,680	293,210	58,042	Nov 08 12:48 PM
BARRY FLANNELLY	Officer	Nov 06 '24	Proposed Sale	79.68	3,680	293,210		Nov 06 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INCY

Incyte Corp

Upgrade your FINVIZ experience